biostudies-literatureFacon TNCI NIH HHS301-310https://www.ebi.ac.uk/biostudies/studies/S-EPMC5774211biostudies-literatureUnknown131(3)This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.59-0.79; <i>P</i> < .00001) and BloodFinal analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.PMC5774211P50 CA186781Catalano JVMohty MHouck VCavo MMoreau PAnderson KCBinder DQiu LLeleu XDispenzieri AErvin-Haynes ADelforge MOriol ABanos ADimopoulos MALee JJWhite DFacon TDe La Rubia JRoussel MWeisel KCavenagh JDChen GBahlis NJGeraldes CBoyle EChen CManier SPerrot ABenboubker LHulin CAttal MTiab MPinto ALudwig HLu JBelch AAvet-Loiseau HArnulf BfalseFinal analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks). The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final analysis prespecified ≥60 months' follow-up). Patients were randomized to Rd continuous (n = 535), Rd18 (n = 541), or MPT (n = 547). At a median follow-up of 67 months, PFS was significantly longer with Rd continuous vs MPT (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.59-0.79; <i>P</i> < .00001) and 2018-01-01T00:00:00Z2018 Jan2026-05-02T19:25:32.358Z2019-03-26T23:52:41ZS-EPMC57742112915042110.1182/blood-2017-07-795047